Our study demonstrates a novel mechanism by which tumor cells acquire resistance to conventional chemotherapeutics upon engagement of the PD-1/PD-L1 axis and strengthen the rationale for combination chemotherapy/immunotherapy in the clinical setting. The gene discussed is CD274; the disease is neoplasm.